<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1109">
  <stage>Registered</stage>
  <submitdate>27/02/2006</submitdate>
  <approvaldate>27/02/2006</approvaldate>
  <nctid>NCT00306982</nctid>
  <trial_identification>
    <studytitle>Incidence of Influenza, Downstream Complications of Influenza &amp; Hospitalizations in Elderly Vaccinated With Fluarix</studytitle>
    <scientifictitle>An Observational Study to Investigate the Incidence of Influenza, Downstream Complications of Influenza and Hospitalizations, in Elderly Subjects Vaccinated With GSK Biologicals' Influenza Vaccine (Fluarix) Administered Intramuscularly.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>106622</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Fluarix

Other interventions: Fluarix


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

        All subjects must satisfy to the following criteria at study entry:

          -  (1) A male or female age 65 years at the time of the first vaccination,

          -  (2) Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol (e.g., return for follow-up visits, disease reporting by
             phone, and completion of Questionnaires) should be enrolled in the study

          -  (3) Written informed consent obtained from the subject

          -  (4) Availability to follow up by phone during the study period

          -  (5) Subjects with residence status allowing free mixing with general community.</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

        The subject must not be included in the study for:

          -  (1) history of hypersensitivity to a previous dose of influenza vaccine

          -  (2) history of allergy or reactions likely to be exacerbated by any component of the
             vaccine including egg, chicken protein, formaldehyde, thimerosal, gentamicin sulfate
             or sodium deoxycholate,

          -  (3) use of any investigational or non-registered product (drug or vaccine) other than
             the study vaccine(s) within 30 days preceding the first dose of study vaccine, or
             planned use during the study period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1524</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,TAS,VIC,WA</recruitmentstate>
    <hospital>GSK Investigational Site - Garran</hospital>
    <hospital>GSK Investigational Site - Umina</hospital>
    <hospital>GSK Investigational Site - Auchenflower</hospital>
    <hospital>GSK Investigational Site - Kippa Ring</hospital>
    <hospital>GSK Investigational Site - South Brisbane</hospital>
    <hospital>GSK Investigational Site - Hobart</hospital>
    <hospital>GSK Investigational Site - Clayton</hospital>
    <hospital>GSK Investigational Site - Heidelberg Heights</hospital>
    <hospital>GSK Investigational Site - Parkville</hospital>
    <hospital>GSK Investigational Site - Nedlands</hospital>
    <postcode>2606 - Garran</postcode>
    <postcode>2257 - Umina</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode> - Hobart</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3084 - Heidelberg Heights</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Paraná</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate the incidence of influenza, disease and various possible
      downstream complications and hospitalizations or emergency room visits after routine annual
      vaccination of the elderly population with Fluarix.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00306982</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>